AstraZeneca To Shut Indian API Site
This article was originally published in PharmAsia News
AstraZeneca is shuttering its Indian active pharmaceutical ingredient unit in Yelahanka, Bangalore in a move the UK-based firm says was triggered by low export demand for the key product made there.
You may also be interested in...
AstraZeneca expects to invest $90m over five years to shore up its footprint in India – a market where the Anglo-Swedish major has introduced a string of new products but has also had a fair share of challenges.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.